|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Anti-TNF alpha in the treatment of ulcerative colitis:A valid approach for organ-sparing or an expensive option to delay surgery?显示文摘Ulcerative colitis(UC)is an inflammatory bowel disease affecting large bowel with variable clinical course.The history of disease has been modified by the introduction of biologic therapy,in particular Infliximab(IFX),that has demonstrated efficacy in inducing fast symptoms remission,promoting mucosal healing and maintaining long-term remission.However,surgery is still needed for UC patients:in case of failure of medical therapy and if acute complications or a malignancy occurred.Surgical treatment is associated with a short-term postoperative mortality and morbidity respectively of 0%-4%and 30%.In this study we systematically analyzed:the role of IFX in reducing the colectomy rate,the risk of post-operative morbidity in pre-operatively IFX-treated patients and the cost-effectiveness of IFX therapy.Four of 5 analyzed randomized controlled trials demonstrated that therapy with IFX significantly reduces the colectomy rate.Moreover,pre-operative treatment with IFX doesn’t seem to increase post-operative infectious complications.By an economic point of view,the cost-effectiveness of IFX-therapy was demonstrated for UC patients suffering from moderate to severe UC in a study based on a cost estimation of the National Health Service of England and Wales.However,the argument is debated. | Gianluca Rizzo Daniela Pugliese Alessandro Armuzzi Claudio Coco | 2014 | World Journal of Gastroenterology2014，20，17： | 5 |
| 2 | Management of perianal fistulas in Crohn's disease:An upto-date review显示文摘Perianal disease is one of the most disabling manifestations of Crohn's disease.A multidisciplinary approach of gastroenterologist,colorectal surgeon and radiologist is necessary for its management.A correct diagnosis,based on endoscopy,magnetic resonance imaging,endoanal ultrasound and examination under anesthesia,is crucial for perianal fistula treatment.Available medical and surgical therapies are discussedin this review,including new local treatment modalities that are under investigation. | Manuela Marzo Carla Felice Daniela Pugliese Gianluca Andrisani Giammarco Mocci Alessandro Armuzzi Luisa Guidi | 2015 | World Journal of Gastroenterology2015，21，5： | 5 |
| 3 | Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study显示文摘 | Filippo Cremonini Simona Di Caro Marcello Covino Alessandro Armuzzi Maurizio Gabrielli Luca Santarelli Enrico C Nista Giovanni Cammarota Giovanni Gasbarrini Antonio Gasbarrini | 2002 | The American Journal of Gastroenterology2002，，11： | 2 |
| 4 | Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents显示文摘 | Alfredo Papa Carla Felice Manuela Marzo Gianluca Andrisani Alessandro Armuzzi Marcello Covino Giammarco Mocci Daniela Pugliese Italo De Vitis Antonio Gasbarrini Gian Lodovico Rapaccini Luisa Guidi | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 5 | Lack of endoscopic visualization of intestinal villi with the “immersion technique” in overt atrophic celiac disease显示文摘 | Antonio Gasbarrini Veronica Ojetti Lucio Cuoco Giovanni Cammarota Alessio Migneco Alessandro Armuzzi Paolo Pola Giovanni Gasbarrini | 2003 | Gastrointestinal Endoscopy2003，，3： | 2 |
| 6 | Lack of endoscopic visualization of intestinal villi with the “immersion technique” in overt atrophic celiac disease显示文摘 | Antonio Gasbarrini Veronica Ojetti Lucio Cuoco Giovanni Cammarota Alessio Migneco Alessandro Armuzzi Paolo Pola Giovanni Gasbarrini | 2003 | Gastrointestinal Endoscopy2003，，3： | 1 |
| 7 | Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year显示文摘 | Luisa Guidi Manuela Marzo Gianluca Andrisani Carla Felice Daniela Pugliese Giammarco Mocci Olga Nardone Italo De Vitis Alfredo Papa Gianlodovico Rapaccini Franca Forni Alessandro Armuzzi | 2014 | Digestive and Liver Disease2014，，11： | 1 |
| 8 | Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13 C-octanoate breath test显示文摘 | Luca Miele Antonio Grieco Alessandro Armuzzi Marcello Candelli Alessandra Forgione Antonio Gasbarrini Giovanni Gasbarrini | 2003 | The American Journal of Gastroenterology2003，，10： | 1 |
| 9 | Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease显示文摘 | Alessandro Armuzzi Gert Van Assche Walter Reinisch Guillaume Pineton de Chambrun Anne Griffiths Malgorzata Sladek Jan C. Preiss Milan Lukas Geert D’Haens | 2012 | Journal of Crohn’s and Colitis2012，，4： | 1 |
| 10 | Update on the management of inflammatory bowel disease: specific role of adalimumab显示文摘 | Luisa Guidi Alessandro Armuzzi Daniela Pugliese | 2011 | 2011 (defa)2011，，： | 1 |
| 11 | Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection显示文摘 | Antonio Gasbarrini Veronica Ojetti Dario Pitocco Francesco Franceschi Marcello Candelli Elena Sanz Torre Maurizio Gabrielli Giovanni Cammarota Alessandro Armuzzi Roberto Pola Paolo Pola Giovanni Ghirlanda Giovanni Gasbarrini | 1999 | European Journal of Gastroenterology & Hepatology1999，，7： | 1 |
| 12 | Adalimumab in active ulcerative colitis: A “real-life” observational study显示文摘 | Alessandro Armuzzi Livia Biancone Marco Daperno Alessandra Coli Daniela Pugliese Vito Annese Annalisa Aratari Sandro Ardizzone Paola Balestrieri Fabrizio Bossa Maria Cappello Fabiana Castiglione Michele Cicala Silvio Danese Renata D’Incà Pietro Dulbecco G | 2013 | Digestive and Liver Disease2013，，： | 1 |
| 13 | Effect of different probiotic preparations on anti- Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study显示文摘 | Filippo Cremonini Simona Di Caro Marcello Covino Alessandro Armuzzi Maurizio Gabrielli Luca Santarelli Enrico C Nista Giovanni Cammarota Giovanni Gasbarrini Antonio Gasbarrini | 2002 | The American Journal of Gastroenterology2002，，11： | 1 |
| 14 | What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?显示文摘The use of biological agents and immunomodulators for inflammatory bowel disease(IBD) is associated with an increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review. | Gianluca Andrisani Alessandro Armuzzi Manuela Marzo Carla Felice Daniela Pugliese Alfredo Papa Luisa Guidi | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，3： | 0 |
| 15 | A rare case of epiploic appendagitis in a patient affected by ulcerative colitis on vedolizumab therapy显示文摘Introduction Epiploic appendagitis(EA)is an acute inflammation of the pedunculated mesenteric fat attached to the colonic surface,distinguished into two forms:primary EA,seemingly elicited by local ischaemic factors;and secondary EA(SEA),elicited by the inflammation of the adjacent organs,with diverticulitis being the most common trigger[1].Few case series have described the association between SEA and inflammatory bowel disease(IBD);however,information about clinical,laboratory and imaging findings,outcomes,and the impact of IBD-specific therapy were not reported.We first report the case of a woman affected by ulcerative colitis(UC)who developed a SEA during vedolizumab therapy(Figure 1A). | Daniela Pugliese Giuseppe Privitera Luigi Larosa Valentin Calvez Diana Broglia Nicoletta de Matthaeis Alessandro Armuzzi | 2022 | Gastroenterology Report2022，10，1： | 0 |
| 16 | Artificial intelligence and inflammatory bowel disease: Where are we going?显示文摘Inflammatory bowel diseases,namely ulcerative colitis and Crohn’s disease,are chronic and relapsing conditions that pose a growing burden on healthcare systems worldwide.Because of their complex and partly unknown etiology and pathogenesis,the management of ulcerative colitis and Crohn’s disease can prove challenging not only from a clinical point of view but also for resource optimization.Artificial intelligence,an umbrella term that encompasses any cognitive function developed by machines for learning or problem solving,and its subsets machine learning and deep learning are becoming ever more essential tools with a plethora of applications in most medical specialties.In this regard gastroenterology is no exception,and due to the importance of endoscopy and imaging numerous clinical studies have been gradually highlighting the relevant role that artificial intelligence has in inflammatory bowel diseases as well.The aim of this review was to summarize the most recent evidence on the use of artificial intelligence in inflammatory bowel diseases in various contexts such as diagnosis,follow-up,treatment,prognosis,cancer surveillance,data collection,and analysis.Moreover,insights into the potential further developments in this field and their effects on future clinical practice were discussed. | Leonardo Da Rio Marco Spadaccini Tommaso Lorenzo Parigi Roberto Gabbiadini Arianna Dal Buono Anita Busacca Roberta Maselli Alessandro Fugazza Matteo Colombo Silvia Carrara Gianluca Franchellucci Ludovico Alfarone Antonio Facciorusso Cesare Hassan Alessandro Repici Alessandro Armuzzi | 2023 | World Journal of Gastroenterology2023，29，3： | 0 |
| 17 | Orphan patients with inflammatory bowel disease-when we treat beyond evidence显示文摘Inflammatory bowel disease(IBD)is a chronic condition that requires continuous medical treatment.To date,the medical management of patients with moderatelyto-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs.Such therapies are licenced after passing through three phases of randomized controlled trials(RCTs),and are subsequently adopted in clinical practice.However,the real-life population of IBD patients who require these therapies can significantly differ from those included in RCTs.As a matter of fact,there is a number of exclusion criteria–nearly ubiquitous in all RCTs–that prevent the enrolment of specific patients:Chronic refractory pouchitis or isolated proctitis in ulcerative colitis,short-bowel syndrome and stomas in Crohn’s disease,ileorectal anastomosis in both ulcerative colitis and Crohn’s disease,and elderly age are some representative examples.In this frontier article,we aim to give an overview of current literature on this topic,in order to address the main knowledge gaps that need to be filled in the upcoming years. | Giuseppe Privitera Daniela Pugliese Loris Riccardo Lopetuso Franco Scaldaferri Alfredo Papa GianLodovico Rapaccini Antonio Gasbarrini Alessandro Armuzzi | 2021 | World Journal of Gastroenterology2021，27，47： | 0 |
| 18 | Clinical and epidemiological features of ulcerative colitis patients in Sardinia,Italy:Results from a multicenter study显示文摘BACKGROUND There are little data on the epidemiological and clinical features of adult patients with ulcerative colitis(UC) in the different Italian regions,mainly derived from the absence of a national registry.This prevents correct interpretation of the disease burden.AIM To assess the main clinical and epidemiological features of adult patients diagnosed with UC in Sardinia,Italy.METHODS We performed a multicenter,observational,cross-sectional study that included adult patients with UC enrolled in seven gastroenterology unit centers in Sardinia.Data were obtained from the patients’ medical records and from a questionnaire administered at the inclusion visit.RESULTS Four hundred and forty-two patients with UC were included.The median age at diagnosis was 39years(interquartile range 28-48).After a median disease duration of 10 years,53 patients experienced proximal extension of proctitis or left-sided colitis.Seventy-five patients developed extraintestinal manifestations.Nineteen patients(4.3%) developed cancer:two with colorectal cancer and seventeen with extracolonic cancers.Mesalazine(5-ASA) remains the mainstay of treatment for UC.Overall,95 patients(21.5%) were treated with one or more biologic agents,whereas 15 patients(3.4%) underwent surgery,mostly colectomy.CONCLUSION Our results provide important insights into the clinical and epidemiological features of patients with UC,and while waiting for a national Italian registry,present eligible data on the UC population in Sardinia. | Salvatore Magrì Mauro Demurtas Maria Francesca Onidi Marcello Picchio Walter Elisei Manuela Marzo Federica Miculan Roberto Manca Maria Pina Dore Bianca Maria Quarta Colosso Antonio Cicu Luigi Cugia Monica Carta Laura Binaghi Paolo Usai Mariantonia Lai Fabio Chicco Massimo Claudio Fantini Alessandro Armuzzi Giammarco Mocci | 2022 | World Journal of Clinical Cases2022，10，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员